Logo

Centus Reports Results of FKB238 (bevacizumab- biosimilar) in P-III AVANA Trial for the Treatment of Advanced/Recurrent nonsq.NSCLC

Share this

Centus Reports Results of FKB238 (bevacizumab- biosimilar) in P-III AVANA Trial for the Treatment of Advanced/Recurrent nonsq.NSCLC

Shots:

  • The P-III AVANA trial compares the efficacy and safety of FKB238 (IV- 15 mg/kg) vs Avastin in a ratio (1:1) in patients with advanced/recurrent non-sq.NSCLC
  • Results: ORR (51.6% vs 53.7%); m-PFS (7.72 vs 7.62 mos.); m-OS (14.13 vs 16.95 mos.)- TEAEs was 94.2% and 95.1%- patients experienced grade 3 or higher TEAEs (53.6% and 55.5%) respectively
  • Currently- two bevacizumab biosimilars have been available in the US i.e.- Mvasi (Amgen) and Zirabev (Pfizer) that launched in July’19 & Dec’19 respectively. FKB238 is currently under FDA’s review while the P-I study demonstrated PK properties & good tolerability without antidrug Ab development

Ref: Center for biosimilar| Image: Centus

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions